Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Daniel Martín(Townsville Hospital), Dante J. Pieramici(California Retina Consultants), Juan E. Grunwald(University of Pennsylvania), Cynthia A. Toth(Duke University), Glenn J. Jaffe(Duke University), Maureen G. Maguire(Penn Presbyterian Medical Center), Jiayan Huang(University of Pennsylvania), John A. Wells(Palmetto Retina Center), Michael L. Klein(Oregon Health & Science University), Ebenezer Daniel(University of Pennsylvania)
Cited by 310
Related Papers
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
|Ophthalmology|2016|702
Adalimumab in Patients with Active Noninfectious Uveitis
|New England Journal of Medicine|2016|646